BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 23379261)

  • 1. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
    Li Y; Meeran SM; Patel SN; Chen H; Hardy TM; Tollefsbol TO
    Mol Cancer; 2013 Feb; 12():9. PubMed ID: 23379261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arsenic‑induced BRCA1 CpG promoter methylation is associated with the downregulation of ERα and resistance to tamoxifen in MCF7 breast cancer cells and mouse mammary tumor xenografts.
    Selmin OI; Donovan MG; Skovan B; Paine-Murieta GD; Romagnolo DF
    Int J Oncol; 2019 Mar; 54(3):869-878. PubMed ID: 30664189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.
    Barone I; Brusco L; Gu G; Selever J; Beyer A; Covington KR; Tsimelzon A; Wang T; Hilsenbeck SG; Chamness GC; Andò S; Fuqua SA
    J Natl Cancer Inst; 2011 Apr; 103(7):538-52. PubMed ID: 21447808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells.
    Kim SS; Lee MH; Lee MO
    Breast Cancer Res Treat; 2020 Feb; 180(1):45-54. PubMed ID: 31897900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
    Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
    Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
    Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
    [No Abstract]   [Full Text] [Related]  

  • 7. CUL4B renders breast cancer cells tamoxifen-resistant via miR-32-5p/ER-α36 axis.
    Wang Y; Pan X; Li Y; Wang R; Yang Y; Jiang B; Sun G; Shao C; Wang M; Gong Y
    J Pathol; 2021 Jun; 254(2):185-198. PubMed ID: 33638154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier.
    Ma W; Sun J; Xu J; Luo Z; Diao D; Zhang Z; Oberly PJ; Minnigh MB; Xie W; Poloyac SM; Huang Y; Li S
    Theranostics; 2020; 10(6):2463-2478. PubMed ID: 32194813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Effects of Dietary Soybean Genistein on Triple-Negative Breast Cancer via Regulation of Epigenetic Mechanisms.
    Sharma M; Arora I; Chen M; Wu H; Crowley MR; Tollefsbol TO; Li Y
    Nutrients; 2021 Nov; 13(11):. PubMed ID: 34836197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine resistant breast cancer cells with loss of ERα expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage.
    Yu S; Gong X; Ma Z; Zhang M; Huang L; Zhang J; Zhao S; Zhu T; Yu Z; Chen L
    Cell Oncol (Dordr); 2020 Feb; 43(1):65-80. PubMed ID: 31701491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Curcumin in Comparison with Trichostatin A on the Reactivation of Estrogen Receptor Alpha gene Expression, Cell Growth Inhibition and Apoptosis Induction in Hepatocellular Carcinoma Hepa 1-6 Cell lLine.
    Sanaei M; Kavoosi F; Arabloo M
    Asian Pac J Cancer Prev; 2020 Apr; 21(4):1045-1050. PubMed ID: 32334468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer.
    Zheng XQ; Guo JP; Yang H; Kanai M; He LL; Li YY; Koomen JM; Minton S; Gao M; Ren XB; Coppola D; Cheng JQ
    Oncogene; 2014 Oct; 33(42):4985-96. PubMed ID: 24166501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Norcantharidin regulates ERα signaling and tamoxifen resistance via targeting miR-873/CDK3 in breast cancer cells.
    Zhang X; Zhang B; Zhang P; Lian L; Li L; Qiu Z; Qian K; Chen A; Liu Q; Jiang Y; Cui J; Qi B
    PLoS One; 2019; 14(5):e0217181. PubMed ID: 31120927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-190 enhances endocrine therapy sensitivity by regulating SOX9 expression in breast cancer.
    Yu Y; Yin W; Yu ZH; Zhou YJ; Chi JR; Ge J; Cao XC
    J Exp Clin Cancer Res; 2019 Jan; 38(1):22. PubMed ID: 30658681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-Hydroxytamoxifen enhances sensitivity of estrogen receptor α-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion.
    Wang G; Qin S; Zayas J; Ingle JN; Liu M; Weinshilboum RM; Shen K; Wang L
    Breast Cancer Res Treat; 2019 Jun; 175(3):567-578. PubMed ID: 30937657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches.
    Rizzo P; Miao H; D'Souza G; Osipo C; Song LL; Yun J; Zhao H; Mascarenhas J; Wyatt D; Antico G; Hao L; Yao K; Rajan P; Hicks C; Siziopikou K; Selvaggi S; Bashir A; Bhandari D; Marchese A; Lendahl U; Qin JZ; Tonetti DA; Albain K; Nickoloff BJ; Miele L
    Cancer Res; 2008 Jul; 68(13):5226-35. PubMed ID: 18593923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An epigenomic approach to therapy for tamoxifen-resistant breast cancer.
    Feng Q; Zhang Z; Shea MJ; Creighton CJ; Coarfa C; Hilsenbeck SG; Lanz R; He B; Wang L; Fu X; Nardone A; Song Y; Bradner J; Mitsiades N; Mitsiades CS; Osborne CK; Schiff R; O'Malley BW
    Cell Res; 2014 Jul; 24(7):809-19. PubMed ID: 24874954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapamycin enhances the sensitivity of ER‑positive breast cancer cells to tamoxifen by upregulating p73 expression.
    Zhu L; Li XX; Shi L; Wu J; Qian JY; Xia TS; Zhou WB; Sun X; Zhou XJ; Wei JF; Ding Q
    Oncol Rep; 2019 Jan; 41(1):455-464. PubMed ID: 30542717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combinatorial epigenetic mechanisms of sulforaphane, genistein and sodium butyrate in breast cancer inhibition.
    Sharma M; Tollefsbol TO
    Exp Cell Res; 2022 Jul; 416(1):113160. PubMed ID: 35447103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The DEK oncogene is a target of steroid hormone receptor signaling in breast cancer.
    Privette Vinnedge LM; Ho SM; Wikenheiser-Brokamp KA; Wells SI
    PLoS One; 2012; 7(10):e46985. PubMed ID: 23071688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.